Authors
Mayank Jha, Deep Chahodiya, Kruti Matawala, Maryam Kharal, Laxi Thaker, Darshil Maheta, Hritvik Jain, Pawan Daga, Siddharth Agarwal, William H Frishman, Wilbert S Aronow
Published in
Cardiology in review. Jun 29, 2026. Epub Jun 29, 2026.
Abstract
Obicetrapib is a cholesteryl ester transfer protein inhibitor that demonstrated reductions in atherogenic lipoproteins. We systematically searched PubMed, Scopus, and Clinicaltrials.gov for relevant randomized controlled trials from inception until September 2, 2025 to evaluate the efficacy and safety outcomes of obicetrapib as a standalone and add-on therapy. The mean difference (MD) with 95% confidence intervals (CI) was pooled using a random effects model. A total of 3512 patients were included. Obicetrapib significantly reduced low-density lipoprotein cholesterol [MD, -37.45 (95% CI, -43.76 to -31.15), P < 0.001], non-high-density lipoprotein (HDL) cholesterol [MD, -32.04 (95% CI, -38.49 to -25.60), P < 0.001], apolipoprotein B [MD, -24.71 (95% CI, -30.79 to -18.63), P < 0.001] and apolipoprotein A [MD, -39.10 (95% CI, -45.35 to -32.85), P < 0.001]. It significantly increased total cholesterol [MD, +10.41 (95% CI, 3.68-17.15), P < 0.001], HDL cholesterol [MD, +147.98 (95% CI, 129.23-166.54), P < 0.001], apolipoprotein A1 [MD, 55.54 (95% CI, 43.37-67.71)], and apolipoprotein E [MD, 53.24 (95% CI, 39.04-67.44), P < 0.001]. As an add-on therapy to ezetimibe, obicetrapib yielded greater reduction in low-density lipoprotein [MD, -51.99 (95% CI, -61.61 to -42.37), P < 0.001] and non-HDL [MD, -50.32 (-55.42 to -45.21), P < 0.001]. No significant effects were observed when combined with statins.
PMID:
42413044
Bibliographic data and abstract were imported from PubMed on 08 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0